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Abstract
We have shown previously that, in sheep primary pituitary
cells, bone morphogenetic proteins (BMP)-4 inhibits FSHb
mRNA expression and FSH release. In contrast, in mouse
LbT2 gonadotrophs, others have shown a stimulatoryeffect of
BMPs on basal or activin-stimulated FSHb promoter-driven
transcription. As a species comparison with our previous
results, we used LbT2 cells to investigate the effects of BMP-4
on gonadotrophin mRNA and secretion modulated by
activin and GnRH. BMP-4 alone had no effect on FSH
production, but enhanced the activinCGnRH-induced
stimulation of FSHb mRNA and FSH secretion, without
any effect on follistatin mRNA. BMP-4 reduced LHb
mRNA up-regulation in response to GnRH (Gactivin)
and decreased GnRH receptor expression, which would
favour FSH, rather than LH, synthesis and secretion. In
contrast to sheep pituitary gonadotrophs, which express only
BMP receptor types IA (BMPRIA) and II (BMPRII), LbT2
cells also express BMPRIB. Smad1/5 phosphorylation
induced by BMP-4, indicating activation of BMP signalling,
was the same whether BMP-4 was used alone or combined
with activinGGnRH. We hypothesized that activin and/or
GnRH pathways may be modulated by BMP-4, but neither
the activin-stimulated phosphorylation of Smad2/3 nor the
GnRH-induced ERK1/2 or cAMP response element-
binding phosphorylation were modiﬁed. However, the
GnRH-induced activation of p38 MAPK was decreased by
BMP-4. This was associated with increased FSHb mRNA
levels and FSH secretion, but decreased LHb mRNA levels.
These results conﬁrm 1. BMPs as important modulators of
activin and/or GnRH-stimulated gonadotrophin synthesis
and release and 2. important species differences in these
effects, which could relate to differences in BMP receptor
expression in gonadotrophs.
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Introduction
The gonadotrophins, luteinizing hormone (LH) and follicle-
stimulating hormone (FSH), are produced by the gonado-
troph cells of the anterior pituitaryand play important roles in
reproductive function. Tight control over the production of
t h e s eh o r m o n e si sc r u c i a l ,p a r t i c u l a r l yi nf e m a l e s ,t o
coordinate follicle selection and terminal follicular growth
as well as the timing and number of ovulations. Synthesis and
release of LH and FSH are regulated by hypothalamic
gonadotrophin-releasing hormone (GnRH) and gonadal
steroids. Despite these common regulators, divergences in
the circulating patterns of LH and FSH are often
encountered, suggesting that these regulators act differentially
on the production of LH and FSH and/or that other factors
are speciﬁcally involved in the control of FSH synthesis.
While the pulsatile pattern of GnRH release is essential for
the activation and secretion of both gonadotrophins, changes
in pulse frequency observed during the oestrous cycle
differentially affect the LH and FSH production. High
frequencies of GnRH pulses are associated with greater LH
secretion whereas lower frequencies favour FSH secretion
(Wildt et al. 1981, Dalkin et al. 1989, Kaiser et al. 1997,
Molter-Gerard et al. 1999). In addition, the FSH secretion is
controlled, independently of LH, by transforming growth
factor-b (TGFb) superfamily members such as activins
and inhibins. Activin, a dimer of two highly related
b-subunits (bA and/or bB), stimulates FSHb gene expression
and FSH release, whereas inhibin, a heterodimer composed of
one a-subunit and one b-subunit (bA or bB), decreases FSH
synthesis and release (Carroll et al. 1989). Activin is secreted
by the gonads and within the pituitary, where it acts as an
autocrine and/or paracrine regulator of FSH synthesis.
Recently, other members of the TGFb superfamily, the
bone morphogenetic proteins (BMPs), were shown to
modulate preferentially FSH secretion. In ovine pituitary
cells, BMP-4 (50 ng/ml) and BMP-6 (100 ng/ml) inhibited
FSHb mRNA expression and FSH release (Faure et al. 2005).
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pituitary cells, BMP-6 and BMP-7, at higher concentrations
(1 mg/ml), BMP-2 and BMP-15 (100 ng/ml) were able to
stimulate basal FSH secretion and FSHb promoter activity
(Huang et al. 2001, Otsuka & Shimasaki 2002, Lee et al.
2007). This difference of BMP effect between the mouse and
the sheep could reﬂect a dissimilar pattern of BMP receptors
on gonadotroph cells driving different signalling pathways.
Alternatively, different BMPs could differentially affect
FSH synthesis.
The TGFb superfamily members act through two types of
serine/threonine kinase receptors, type I and type II (for
review: Miyazawa et al. 2002, Shimasaki et al. 2004). Activin
signals through activin receptor types IIA (ActRIIA) or IIB
(ActRIIB) and activin receptor type IB (ActRIB, also known
as activin receptor-like kinase 4 or ALK-4). Speciﬁc BMP
signalling requires BMP receptor type II (BMPRII) and BMP
receptor types IA (BMPRIA or ALK-3) or IB (BMPRIB or
ALK-6). The ligand-type II receptor complex induces
phosphorylation and activation of type I receptors that in
turn trans-phosphorylate receptor-activated Smad proteins
within the cytoplasm. These then interact with common
Smad4, and the resulting complex translocates to the nucleus
to affect gene transcription. Activin leads to the speciﬁc
activation of Smads 2 and 3, whereas BMPs activate Smads 1,
5 and 8. The combinations of activin and BMP ligands and
receptors are not unique. For example, ActRIIA and
ActRIIB can bind to BMP-6 (Ebisawa et al. 1999), whereas
BMPRII binds speciﬁcally to BMP ligands (Liu et al. 1995,
Nohno et al. 1995). Regarding type I receptors, ActRIA (also
known as ALK-2) has been identiﬁed as a type-I receptor for
BMPs (Macias-Silva et al. 1998).
To further explore BMP action at the gonadotroph cell
level, we have examined the effects of BMP-4 on mouse
LbT2 cell LH and FSH b-subunit mRNA levels and
gonadotrophin release. Considering that activin and GnRH
are important modulators of FSH synthesis, it is of interest to
determine if BMP-4 interacts with these two factors and to
explore the signalling pathways through which BMP-4 exerts
its effect.
Materials and Methods
Cell culture
Mouse LbT2 cells (provided by Dr P Mellon, University of
California, San Diego, CA, USA) were routinely maintained
in Dulbecco’s modiﬁed Eagle’s medium (DMEM) with 10%
foetal calf serum (Hyclone, Logan, UT, USA) on ﬂasks coated
with Matrigel (1:29; BD Biosciences Clontech, Cowley,
Oxford, UK). For experimental purposes LbT2 cells were set
up as described previously (Nicol et al. 2004) at a density of
2.75!10
6/well. After overnight incubation, cells were
treated with 0 or 50 ng/ml recombinant human activin A
(R&D Systems, Abingdon, Oxon, UK) Ga daily 1-h pulse of
10 nM GnRH (Bachem, St Helens, Merseyside, UK), in the
presence or absence of 50 ng/ml recombinant human BMP-4
(R&D Systems) for 3 days. Media were collected daily for
measurement of secreted FSH and LH by RIA. On day 4,
total RNA was extracted from cells for the measurement of
FSHb,L H b, GnRH receptor (GnRH-R) and follistatin
mRNA levels by quantitative RT-PCR. In addition, on
day 4, after a ﬁnal pulse of GnRH, protein extracts were
prepared for western blot analysis.
Mouse FSH and LH RIAs
RIAs for mouse FSH and LH were performed as previously
described (McNeilly et al. 1996), using reagents supplied
by Dr A Parlow (NHPP, Harbor-UCLA, Torrance, CA,
USA).Theminimumdetectableconcentrationswere1 ng/ml
and 200 pg/ml for FSH and LH respectively. The intra- and
inter-assaycoefﬁcientsofvariationwere!10%forbothassays.
Qualitative RT-PCR
The expression of BMP receptor mRNA in LbT2 cells was
assessed by RT-PCR, using adult mouse pituitary as a positive
control. Total RNA was extracted using TRI Reagent
(Sigma–Aldrich Ltd). Aliquots were treated with DNase
I using DNA-free (Ambion (Europe) Ltd, Huntingdon,
Cambs, UK) and reverse transcribed, using random hexam-
ers, with Taqman Reverse Transcription reagents (PE
Biosystems, Warrington, Cheshire, UK) according to
manufacturers protocol. PCR was performed for 35 cycles
using ThermoStart Taq DNA polymerase (Abgene, Epsom,
Surrey, UK). Primer sequences were as follows: BMPRIA:
fwd: CCTGTTGTTATAGGTCCGTT; rev: TCTCCT-
ACTGGAATAAATGC; BMPRIB: fwd: AGATTGGAAA-
AGGCCGCTATG; rev: GATGTCAACCTCATTTGTG-
TC; BMPRII: fwd: GAGGACTGGCTTATCTTCAC; rev:
AGCTCCTTCTAGCACTTCTG. Predicted product sizes
were 194, 473 and 245 bp respectively.
Immunostaining
LbT2 cells, cultured on Labtek II chamber slides (Fisher
Scientiﬁc UK, Manchester, UK) were washed with PBS,
ﬁxed in Bouin’s solution for 5 min, washed and then
permeabilized using 10% normal goat serum, 1% BSA in
PBS (blocking solution) containing 0.2% Igepal CA-630 for
20 min at room temperature. After washing, cells were
blocked for 1 h, then incubated at 4 8C overnight with rabbit
polyclonal antibodies directed against BMPRIA, BMPRIB
(ten Dijke et al. 1994) or BMPRII (Rosenzweig et al. 1995),
diluted at 1:50. Antibodies were kindly donated by Dr C-H
Heldin (Ludwig Institute for Cancer Research, Uppsala,
Sweden). Negative controls were performed with 1:100 goat
serum in place of the primary antibody. Slides were washed
and then incubated at room temperature for 1 h with goat
anti-rabbit Alexa 488 (Molecular Probes, Eugene, OR, USA)
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Permaﬂuor ﬂuorescent mounting medium (Beckman Coul-
ter, High Wycombe, UK) and examined using a LSM 510
confocal microscope (Carl Zeiss Ltd, Welwyn Garden City,
Herts, UK).
Quantitative RT-PCR
Levels of mRNA for FSHb,L H b, GnRH-R and follistatin
were measured using Taqman RT-PCR. Primer and probe
sequences were designed using Primer Express software and
synthesized by PE Biosystems or by Biosource Europe SA
(Nivelles, Belgium). FSHb,L H b and GnRH-R primer/
probe sequences have been previously reported (Nicol et al.
2004). The sequences for follistatin were as follows: fwd:
GGGCTGGATGGGAAAACCTA; rev: CGGCTGCTC-
TTTGCATCTG; probe (FAM labelled): CGCAAC-
GAATGTGCACTCCTCAAGG. Ribosomal 18S primers
and probe were from a Taqman Ribosomal RNA Control
Reagents kit (VIC labelled probe). RNA was prepared,
DNase I-treated and reverse transcribed as described above.
RNAwas added to RTreactions at 10 ng/ml. A PCR mix was
prepared, consisting of Taqman Universal PCR Master Mix
(1!), gene speciﬁc forward and reverse primers (300 nM
each) and probe (200 nM), and ribosomal 18S forward and
reverse primers (50 nM each) and probe (200 nM). This was
aliquoted into tubes, then cDNA was added at 1 ml/25 ml
reaction mix. Aliquots (25 ml) were transferred to wells in a
96-well PCR plate, with each sample run in duplicate. Plates
were sealed with optical adhesive covers and the PCRs run on
ABI Prism 7900HT PCR machine using standard conditions.
Controls included cDNA prepared with omission of reverse
transcriptase. Prior to analysis, a validation assay was
performed to demonstrate that ampliﬁcation of target genes
and the reference (18S) were approximately equal. Quantiﬁ-
cation of speciﬁc mRNA levels was performed by the DDCt
method (Bulletin no.2; PE Biosystems). Standard PCRs using
each set of primers were run on an agarose gel to conﬁrm
ampliﬁcation of a single product of the correct size. Unless
otherwise stated all reagents, equipment and software were
from PE Biosystems.
Western blotting
To investigate activation of Smads, ERK1/2, p38 MAPK and
cAMP response element-binding protein (CREB), LbT2
cells were treated as described above except that on day 4, a
ﬁnal pulse of GnRH was given (duration of 1 h for Smad
studyand 10 or 20 min for ERK1/2, p38 and CREB studies).
The cells were then washed with ice-cold PBS and lysed in
buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl,
1 mM EDTA, 1 mM EGTA, 1% Triton X-100, 0.5% Igepal
CA-630, 100 mM sodium ﬂuoride, 10 mM sodium pyro-
phosphate, 10 mM sodium orthovanadate, protease inhibitor
cocktail. The protein concentration was determined using
a Bio-Rad DC protein assay (Bio-Rad Laboratories Ltd).
After 5 min at 95 8C in reducing buffer, proteins were
separated on SDS-PAGE gels and electroblotted onto
Immobilon membranes (Millipore Corporation, Bedford,
MA, USA). For Smad and ERK analysis, membranes were
blocked for 1 h at room temperature in Tris-buffered saline,
0.1% Tween (TBST) containing 5% fat-free dry milk and
then incubated in primary antibody overnight at 4 8C. The
P-Smad1/5 rabbit monoclonal, P-ERK1/2 and total
ERK1/2 polyclonal antibodies were from Cell Signaling
Technology (Danvers, MA, USA) and were all used at 1:1000
dilution. The Smad1/5 and Smad2/3 polyclonal antibodies
were from Upstate Biotechnology (Lake Placid, NY, USA)
and were used at 1:500 and 1:1000 dilutions respectively. The
P-Smad2/3 antibody was provided by Dr C-H Heldin
(Ludwig Institute for Cancer Research, Uppsala, Sweden)
and used at 1:2000 dilutions. After washing in TBST, the
membranes were incubated with Amersham ECL peroxidase-
labelled anti-rabbit antibody (GE Healthcare UK Ltd, Little
Chalfont, Bucks, UK) for 1 h at room temperature.
Immunoreactive proteins were detected using Amersham
ECL Plus western blotting detection reagents and exposure to
Hyperﬁlm ECL (both from GE Healthcare UK Ltd). For
quantiﬁcation, the membranes were scanned on a Typhoon
9400 variable-mode imager (GE Healthcare UK Ltd). In each
case, the membrane was probed ﬁrst with the antibodyagainst
the phosphorylated protein, then stripped using buffer
containing 2% SDS, 62.5m M T r i s ( p H 6 .8), 0.1M
2-mercaptoethanol for 30 min at 75 8C. After washing,
immunodetection was repeated using antibody against the
total protein. For P-p38 and P-CREB analysis, membranes
were blocked in Odyssey blocking buffer (Licor Biosciences
UK Ltd, Cambridge, UK) and primary antibodies were
diluted in Odyssey buffer diluted 1:1 with PBS, 0.1% Tween
20 (PBST). The primary antibody against the phosphorylated
protein was combined with a monoclonal anti-a-tubulin to
act as loading control for quantitation. The P-p38 and
P-CREB antibodies (Cell Signaling Technology) wereused at
1:1000 dilutions and a-tubulin monoclonal (Sigma) was used
at 1:3000 dilutions. After washing in PBST the membranes
were incubated with a mixtureof goat anti-rabbit IR Dye 680
and goat anti-mouse IR Dye 800CW for 1 h at room
temperature. Immunoreactive proteins were detected and
quantiﬁed using an Odyssey Infrared Imaging System (Licor
Biosciences UK Ltd).
Statistical analysis
Results are reported as meanGS.E.M. from one representative
experiment. Experiments were carried out at least three
times. Analyses of interactions between BMP-4 and other
treatment groups were carried out using two-way ANOVA
and the Bonferroni method. Comparisons between treat-
ments on FSH, LH concentrations, FSHb and LHb mRNA
levels and phosphorylated protein intensities were analysed
by one-way ANOVA followed by Tukey’s multiple compari-
son test. The value of P!0.05 was considered signiﬁcant.
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Results
Expression of BMP receptors in LbT2 gonadotrophs and adult
mouse pituitary
Qualitative RT-PCR analysis of total RNA prepared from
mouse LbT2 gonadotroph cells and adult mouse pituitary was
carried out using primers speciﬁc for BMPRIA (ALK-3),
BMPRIB (ALK-6) and BMPRII. As shown in Fig. 1A,
products of the expected size were observed for all three
receptor types in both LbT2 cells and adult mouse pituitary.
In negative controls, performed by omitting reverse
transcriptase enzyme in RT reactions, no PCR products
were detected (not shown). Particularly in LbT2 cells, the
levels of BMPRIB mRNA appeared to be lower than the
other two receptor types. Immunostaining using speciﬁc
antibodies conﬁrmed the presence of expressed protein for all
three BMP receptor types in LbT2 cells when compared with
a negative control (Fig. 1B).
Effects of BMP-4 on gonadotrophin secretion and FSHb and
LHb mRNA expressions
To determine whether BMP-4 was capable of modifying
gonadotrophin production and secretion in LbT2 gonado-
trophs, cells given activin Ga daily 1 h pulse of GnRH for
three days were also treated with BMP-4. Secretion proﬁles
for FSH and LH, representing the total protein secreted
during day 3 GnRH treatment and the subsequent overnight
incubation, and the corresponding day 4 b-subunit mRNA
levels are shown in Fig. 2. As expected, FSH secretion
increased (P!0.001) in response to activin and this effect was
increased synergistically (P!0.001) in the presence of
GnRH, although GnRH alone had no effect (Fig. 2A).
While BMP-4 alone had no effect on FSH secretion, it
increased the release of FSH in response to activin and
activinCGnRH (P!0.01 and P!0.001 respectively).
Similarly, the FSHb mRNA expression was up-regulated by
activin (P!0.05) and this effect was also increased
synergistically by GnRH (P!0.001; Fig. 2B). BMP-4
alone, or in combination with activin or GnRH, had no
effect on FSHb mRNA, but it further increased activinC
GnRH-stimulated mRNA levels (P!0.01).
LH release from LbT2 cells was stimulated by GnRH
(P!0. 001) and these levels almost doubled when GnRH
was combined with activin (P!0.001, Fig. 2C). BMP-4
alone or in combination with activin and/or GnRH did not
affect LH release. By contrast, while LHb mRNA
expression also increased in response to GnRH and
activinCGnRH (P!0.001), these levels were reduced
(P!0.05) by BMP-4 (Fig. 2D).
Effects of BMP-4 on GnRH-R and follistatin mRNA levels
To investigate the possible underlying mechanisms for the
effects of BMP-4 on gonadotrophin production and release in
LbT2 gonadotrophs, GnRH-R and follistatin mRNA levels
on day 4 from cells treated as described were measured. As
shown in Fig. 3A, activin and GnRH alone produced small
increasesin GnRH-R mRNA levels, butcombined activinC
GnRH was required to achieve a signiﬁcant (P!0.001)
effect. BMP-4 reduced GnRH-R mRNA expression in both
the GnRH- and activinCGnRH-treated cells (P!0.01 and
P!0.001 respectively). Follistatin mRNA levels, on the
other hand, increased in response to activin and activinC
GnRH (P!0.01 and P!0.001 respectively, Fig. 3B).
BMP-4 treatment signiﬁcantly reduced the activin-stimulated
increase in follistatin mRNA (P!0.05), but had no effect on
the increase observed in response to activinCGnRH.
Activation of Smad signalling pathways by BMP-4 and activin
To determine whether or not the BMP and activin signalling
pathways could interact at the Smad activation level, LbT2
cells cultured in the presence or absence of activin Ga daily
1 h pulse of GnRH for 3 days were also exposed to BMP-4.
On day 4, a ﬁnal 1-h pulse of GnRH was given and proteins
extracted for western blot analysis, using antibodies speciﬁc
for P-Smad1/5 and P-Smad2/3, to look at the BMP and
activin signalling pathways respectively. As shown in Fig. 4A,
BMP-4, but not activin, induced the appearance of a band at
w60 kDa, corresponding to the phosphorylated form of
Smad1/5. The presence of activin and/or GnRH with
BMP-4 did not affect the intensity of this band when
compared with BMP-4 treatment alone. By contrast, activin
(G GnRH) induced activation of Smad2/3 as indicated by
increased intensity of band(s) at w55–58 kDa corresponding
to phosphorylated Smad2/3 (Fig. 4B). When cells were
treated with both BMP-4 and activinGGnRH, band
intensity did not change compared with activinGGnRH
alone. It should be noted that the results shown here were
obtained using an antibody against P-Smad2/3 and that two
bands were observed. However, it appeared that the upper
band (P-Smad2) was mainly responsible for the increased
signal in response to activinGGnRH and indeed, identical
results were obtained using an antibody speciﬁc for P-Smad2
(data not shown).
Effects of BMP-4 on the GnRH-induced activation of ERK1/2,
p38 MAPK and CREB
As there is evidence that, as well as signalling through
the Smad pathways, TGFb family members may also utilize
other downstream signalling pathways, we examined
whether or not BMP-4 activated or inﬂuenced the activation
of other pathways known to be active in gonadotrophs.
The LbT2 cells were cultured in the presence or absence of
activin G a daily 1-h pulse of GnRH G BMP-4 for 3 days.
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previously exposed to GnRH and proteins extracted for
western blot analysis, using antibodies speciﬁc for the
phosphorylated forms of ERK1/2, p38 MAPK and CREB.
As expected, GnRH induced ERK1/2 phosphorylation,
with the same effect observed in the presence and absence of
activin (P!0.001; Fig. 5A). BMP-4 had no effect on ERK
activation. The results shown here were from cells that are
given GnRH for 20 min on day 4. After 10-min GnRH
supply the same trend was observed, but the result did not
Figure 1 Expression of BMP receptors. (A) mRNAs for BMP receptors IA, IB and II were detected in untreated
LbT2 cells and adult mouse pituitary by RT-PCR at 35 cycles. (B) BMP receptor proteins IA, IB and II were
detected in untreated LbT2 cells by immunoﬂuorescence. Bar represents 10 mm.
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MAPK was also activated by GnRH (P!0.01), but in this
case activin increased the response observed with GnRH
alone (P!0.05). BMP-4 treatment, in the presence of
activinCGnRH, reduced phosphorylated p38 levels
(P!0.01). In this case, the treatment 10-min GnRH supply
gave the optimum result, as after 20 min GnRH levels of
phosphorylated p38 were unmeasurable in our detection
system. CREB was activated by GnRH alone (P!0.001;
Fig. 5C) and neither activin nor BMP-4 had a signiﬁcant
effect. Again, 20-min GnRH produced the optimum result,
although after 10 min a statistically similar effect was observed
(data not shown).
Discussion
Earlier studies have identiﬁed BMPs as modulators in the
regulation of FSH synthesis and release. In rodent primary
pituitary cells and the mouse LbT2 gonadotroph cell line,
different BMPs (BMP-15, as well as BMP-6 and -7 at high
doses) exert a stimulatory effect on FSHb transcription
(Huang et al. 2001, Otsuka & Shimasaki 2002), whereas in
ovine primary pituitary cells, BMP-4 and BMP-6 have
inhibitory effects on FSHb mRNA expression and FSH
release (Faure et al. 2005).
In the present study we report that, in LbT2 mouse
gonadotroph cells, BMP-4 alone had no effect on FSHb
mRNA and FSH release, as reported previously for BMP-2,
-6 and -7 used at comparable doses (Huang et al. 2001, Lee
et al. 2007). Remarkably, BMP-4 increased both FSHb
mRNA and FSH secretion when combined with activin
A and GnRH. Recent studies observed synergistic effects on
FSHb transcription between BMP-2 and activin A in LbT2
cells (Lee et al. 2007). Moreover, our data show for the ﬁrst
time that LHb mRNA and LH secretion remained unaffected
by BMP-4 treatment but that, interestingly, the up-regulation
of LHb mRNA in response to GnRH was reduced.
Our results underline the opposite actions of BMP-4
on FSH expression in ewe primary pituitary cells and
murine homogeneous gonadotroph cells. In ewe pituitary
cells BMP-4 and BMP-6 decreased both basal and
Figure2 EffectsofBMP-4ongonadotrophinsecretionandFSHbandLHbmRNAexpression.(A)FSHand(C)LH
secretedon day 3 from LbT2 cells cultured with 0 or 50 ng/ml BMP-4 in the presence and absence of 50 ng/ml
activinAGadaily 1 h pulse of10 nMGnRHfor 3 daysweremeasuredby RIA. Resultsrepresenttotal hormone
secretedduringthe 1 hGnRHtreatmentandthesubsequentovernightincubation;nZ5.(B) FSHb and (D) LHb
mRNA levels on day 4 in LbT2 cells, cultured as described, were measured by Taqman quantitative RT-PCR;
nZ3.Differentlettersindicatesigniﬁcantdifferencesbetweentreatmentgroups.ValuesrepresentmeansGS.E.M.
from one representative experiment. Five experiments were performed with similar results.
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(Faure et al. 2005). The reasons for this differential effect are
not clear. They may reﬂect different speciﬁc patterns of BMP
receptors between ewe gonadotroph cells and LbT2 cells
leading to activation of different signalling pathways and/or
different intra-cellular components. The present results
demonstrate that LbT2 cells express mRNAs encoding the
BMP receptors BMPRIA, BMPRIB and BMPRII, con-
ﬁrming data from Lee et al. (2007), in contrast to another
study in which only BMPRIA and BMPRII were found
(Otsuka & Shimasaki 2002). However, in our study,
BMPRIB mRNA does appear to be expressed at lower
levels than BMPRIA and BMPRII. Furthermore,
immunocytochemistry conﬁrmed the presence of proteins
corresponding to the three types of receptors. In contrast to
LbT2 cells, BMPRIB was not detected in ewe gonadotroph
cells (Faure et al. 2005). The bioavailability of different
receptors could dictate the FSH response to BMPs. Even if
Figure 3 Effects of BMP-4 on GnRH-R and follistatin mRNA
expression. LbT2 cells were cultured with 0 or 50 ng/ml BMP-4 in
the presence and absence of 50 ng/ml activin AGa daily 1-h pulse
of 10 nM GnRH for 3 days. On day 4, total RNA was prepared and
(A) GnRH receptor and (B) follistatin mRNA levels were measured
byTaqmanquantitative RT-PCR. Different lettersindicate signiﬁcant
differences between treatment groups. Values represent meansG
S.E.M. from one representative experiment; nZ3. Five experiments
were performed with similar results.
Figure 4 Activation of Smad signalling pathways. LbT2 cells were
cultured with 0 or 50 ng/ml BMP-4 in the presence and absence of
50 ng/ml activin AGa daily 1 h pulse of 10 nM GnRH for 3 days.
On day 4, the cells were given a further 1-h GnRH treatment and
total protein extracts prepared. Levels of (A) phosphorylated
Smad1/5 and (B) phosphorylated Smad2/3 were measured by
western blotting and expressed relative to the respective total Smad
proteins. Different letters indicate signiﬁcant differences between
treatment groups. Values represent meansGS.E.M. from one
representative experiment; nZ2.
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or BMPRIB (ten Dijke et al. 1994), the two receptors may
not be equivalent in activating signalling. Alternatively,
receptors other than BMPRIA or IB could be involved. A
previous report has shown that BMP-2 acts through BMPRII
and ALK-2 in LbT2 cells (Lee et al. 2007). Moreover, ewe
primary pituitary cells are composed of different cell types and
the target cell type(s) for BMP-4 are not known. Whether
BMP-4 acts directly on gonadotroph cells in sheep primary
pituitary cells has yet to be determined.
The nature of the mechanisms by which BMP-4 interacts
with activin and GnRH is still unclear. The classical signalling
pathway used by BMPs involves Smads 1, 5 and 8 activated by
BMP receptors type II and type I. As demonstrated by the
phosphorylation of Smad1/5, BMP-4 activated the BMP
pathway in LbT2 cells. However, BMP-4 alone failed to
modify the level of FSHb or LHb mRNA and gonadotrophin
release. It is possible that Smads 1/5 mediate other responses
to BMP in LbT2 cells such as cell proliferation (Otsuka &
Shimasaki 2002, Takeda et al. 2007). BMP-4 action required
the presence of activin and was ampliﬁed when GnRH was
added in combination with activin. This action was not
accompanied by changes in the level of P-Smad1/5,
suggesting that other signalling proteins and/or pathways
are involved. A recent study suggested that Smad8 might be
the preferred signalling protein in the BMP pathway since
overexpression of Smad8, but not Smad1 or 5, enhanced the
FSHb promoter activity in response to BMP-2 (Lee et al.
2007). It is possible that BMP-4 may be acting through the
modulation of activin and/or GnRH pathway. Previous data
have shown that activin transmits its signal through Smad2
and/or Smad3 phosphorylation (Dupont et al. 2003, Suszko
et al. 2003, Bernard 2004). While we detected an increase in
the phosphorylated forms of Smad2/3 in the presence of
activin, the addition of BMP-4G GnRH in LbT2 cell
medium did not change the level of P-Smad2/3. Thus, the
interaction between BMP-4, activin and GnRH does not
modify Smad1/5 or Smad2/3 phosphorylation.
It is unclear whether follistatin plays a role in this system, as
the effects of BMP-4 on expression offollistatin mRNAwere
inconsistent. Activin-stimulated mRNA was reduced by
BMP-4 treatment, in contrast to activinCGnRH-stimulated
mRNA which remained unaffected. In addition, increased
follistatin synthesis did not have any effect on Smad2/3
Figure 5 Activation of ERK, p38 MAPK and CREB signalling. The
LbT2 cells were cultured with 0 or 50 ng/ml BMP-4 in the presence
and absence of 50 ng/ml activin AGa daily 1-h pulse of 10 nM
GnRH for 3 days. On day 4, the cells were given a ﬁnal GnRH pulse
for 10 or 20 min and levels of (A) phosphorylated ERK1/2 expressed
relative to total ERK1/2, (B) phosphorylated p38 expressed relative
to a-tubulin and (C) phosphorylated CREB expressed relative to
a-tubulin were measured by western blotting. Different letters
indicate signiﬁcant differences between treatment groups. Data
shown for ERK1/2 and CREB are from 20-min GnRH treatment
groups and for p38 from the 10-min GnRH treatment. Values
represent meansGS.E.M. from one representative experiment; nZ2.
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activin and BMP-4 levels used in this study would most likely
be sufﬁcient to completely override any possible effects of
endogenous follistatin, which may be more relevant in vivo,
where levels of endogenous activin and BMPs would be
lower. The ability of follistatin to bind BMPs, albeit with a
lower afﬁnity than activin (Balemans & Van Hul 2002),
suggests it may well be involved in the BMP-mediated
regulation of FSH production in vivo.
Since there is evidence that BMPs can operate through
Smad-independent pathways such as MAPK signalling
molecules (Lou et al. 2000, Xiao et al. 2002, Derynck &
Zhang 2003), changes in levels of phosphorylated ERK1/2
and p38 were measured. As expected, GnRH activated the
phosphorylation of ERK1/2 (Liu et al. 2002), but this
response was not modiﬁed by activin, corroborating previous
data (Gregory et al. 2005). The presence of BMP-4 did not
affect GnRH-mediated activation of ERK1/2. Previous
studies have shown that BMPs can induce the p38 MAPK-
dependent pathway (Iwasaki et al. 1999, Nakamura et al.
1999). In the current study we observed that the level of
GnRH-enhanced p38 activation was increased by activin,
conﬁrming a previous report (Coss et al. 2007), and this
correlated with increased FSHb mRNA and FSH secretion.
This p38 activation in response to GnRHCactivin was
reduced by BMP-4, contrary to the increase in FSHb mRNA
and FSH secretion. As GnRH alone induced the p38
activation, but had no effect on FSHb mRNA and FSH
secretion, which remained equivalent to those in untreated
cells, the exact role of p38 in regulating FSH production is
unclear. The BMP-induced reduction in p38 MAPK does,
however, correlate with a decrease in LHb mRNA
expression. GnRH is also known to activate CREB protein
in gonadotroph cell lines (Duan et al. 1999, Shaﬁee-Kermani
et al. 2007). Our results conﬁrm that GnRH activates CREB,
but CREB phosphorylation was not signiﬁcantly affected by
activin and/or BMP-4. Our current data, therefore, indicate
that the classical upstream activin (Smad2/3) or GnRH
(ERK, CREB) pathways are not modiﬁed in the presence of
BMP-4. The p38 MAPK signalling appears to be modulated
by BMP-4, but whether this has direct effects on FSH
production/secretion remains to be determined. Considering
the synergistic effects of BMP-2 and activin on FSHb
transcription in LbT2 cells, it has recently been suggested that
each ligand employs different, non-overlapping mechanisms
to generate their effects (Lee et al. 2007). A summation of the
independent signalling pathways activated by BMP-4, activin
and GnRH could mediate their combined response with an
ampliﬁed action occurring speciﬁcally at the level of the
FSHb promoter. So far, it is not known if BMP-4 exerts its
effect directly on the FSHb promoter and detailed analyses
will be necessary to localize the site of BMP action.
In addition to its effect on FSHb mRNA and FSH release,
BMP-4 also regulated LHb expression. In the present study,
we obtained clear evidence that BMP-4 decreased levels of
GnRH and activin-induced LHb mRNA. This effect
appeared to be mediated, at least partly, by the down-
regulation of GnRH-R mRNA. The inhibitory effect of
BMP-4 on LHb and GnRH-R mRNA levels is contra-
dictory to the stimulatory action of activin (Pernasetti et al.
2001, Nicol et al. 2004, Yamada et al. 2004). Several studies
indicate a correlation between GnRH-R density and a
differential gonadotrophin response to GnRH (Kaiser et al.
1995, Bedecarrats & Kaiser 2003). High levels of GnRH-R
are associated with preferential LHb gene expression whereas
lower levels favour the stimulation of FSHb gene expression,
suggesting a role for GnRH-R levels in mediating these
differential responses. Thus, we propose that BMP-4, partly
by inhibiting GnRH-R expression, could induce an
inhibition of the LHb mRNA level, potentially through
p38 MAPK activation, and promote an increase in the level of
FSHb mRNA and FSH release. The absence of any effect of
BMP-4 on LH release compared with its effect on LHb
mRNA levels may simply reﬂect the release of stored LH via
the regulated secretory pathway (Nicol et al. 2002, 2004).
In conclusion, our results show that BMP-4, activin and
GnRH act in a synergistic manner to up-regulate FSHb
mRNA and FSH release. By contrast, BMP-4 reduces the
GnRH and/or activin-induced up-regulation of LHb and
GnRH receptor mRNA. We demonstrated that the classical
upstream BMP signalling molecule(s) are activated in the
LbT2 cells by BMP-4, but other signalling molecules/
pathways must be involved in order to obtain the effects on
FSH production observed in response to the interaction of
BMP-4 with activin/GnRH. Naturally, these results need to
be checked in primary cell cultures to determine if the
difference in the effects of BMP-4 in the present mouse LbT2
gonadotroph cell line and our previous studies in sheep
primary cells is due to different paracrine or autocrine
mechanisms involving an interaction with other pituitary cell
types. In contrast to mouse pituitary, BMP-4 mRNAwas not
detected in LbT2 cells (Lee et al. 2007, our unpublished data)
arguing for a paracrine role. Collectively, the present data
reinforce the concept of a role for BMP-4 in the control of
FSH and reveal a novel involvement in LH control.
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